Study of COVID-19 Outbreak in Hospital Departments of Bamako, Mali

Institut National de la Santé Et de la Recherche Médicale, France450 enrolled

Overview

The new coronavirus known as SARS-Cov-2 (severe acute respiratory syndrome -coronavirus 2) was first reported in December 2019 and rapidly became a public health emergency. The COVID-19 pandemic is now affecting sensitive regions with fragile health care systems, such as South America and Africa. Caregivers, in the front line of Covid19 patient management, may accidentally become infected and a source of infection during the incubation phase or in case of asymptomatic infection. The objectives of this project are thus i) to assess SARS-Cov-2 spread over the hospital departments of Bamako by carrying out a systematic molecular screening of patients and caregivers, ii) to evaluate the feasibility of Point-Of-Care molecular assays in Mali and iii) to estimate the immunity acquired from SARS-Cov-2 among health workers through serological testing, allowing also the assessment of asymptomatic caregiver rate and absence of re-infection among the immunized caregivers. Finally, iv) variability of the virus over time and spread of different variants around the world will be studied by sequencing the viral genome.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

SCREENING

Masking

NONE

Enrollment

450

Conditions

Covid19

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Free and informed consent accepted in writing * Patient: patient hospitalized in one of the four hospitals of Bamako, with clinical signs of infection of the upper or lower respiratory tracts (sore throat, cough/sputum, nasal congestion and rhinorrhea, odynophagia, thoracic oppression, dyspnea, desaturation) with fever or feeling of fever or any other signs of SARS-Cov-2 infection (that is to say the following clinical manifestations, of sudden onset: unexplained asthenia, unexplained myalgia, headache without a known migraine disease, anosmia or hyposmia without associated rhinitis, dysgueusia, diarrhea, heart rhythm disorders, acute myocardial injury, severe thromboembolic event) or who have been in close contact with a SARS-CoV-2 infected person without effective protective measures (FFP2/surgical masks or physical separation) and defined as follows: having shared the same place of life as the confirmed case, for example: family, same room or having a direct contact in face to face with less than 1 meter from the confirmed case during a talk; intimate friends; class or office neighbours; adjacent to the index case in a plane or a train; or having provided or received hygiene or care acts from a confirmed case. * Caregivers: caregivers of one of the four hospitals of Bamako Exclusion Criteria: * Persons subject to legal protection or not able to give a free and informed consent. * Caregivers: caregivers not able to follow the project schedule

Locations (4)

Hopital du Point-G

Bamako, Mali

Hopital Gabriel Toure

Bamako, Mali

Hôpital dermatologique de Bamako

Bamako, Mali

Hôpital du Mali

Bamako, Mali

Outcomes

Primary Outcomes

Incidence rate of positive SARS-Cov-2 RT-PCR in Bamako hospital departments during the study

Positive SARS-Cov-2 RT-PCRs are defined by the detection of SARS-Cov-2 genome after amplification using a test targeting 2 regions of the genome.

Time frame: Through the completion of subject participation (up to 15 months after study start date).

Secondary Outcomes

Number of Cepheid Xpert® Xpress SARS-Cov-2 cartridges available for 19.8 USD/number required for the project

Time frame: Through the completion of subject participation (up to 15 months after study start date).

Percentage of positive serological tests among the caregivers of the hospital departments of Bamako.

Time frame: Assessed on the fourth serological assay performed (at Month 3).

Percentage of caregivers asymptomatic but immunized to SARS-CoV-2

Time frame: Assessed on the fourth serological assay performed (at Month 3).

Percentage of caregivers immunized and re-infected with SARS-CoV-2

Time frame: Through the completion of caregiver participation (up to 15 months after study start date).

Number of SARS-CoV-2 mutations/variants detected during the study

Time frame: Through the completion of subject participation (up to 15 months after study start date).

Percentage of SARS-CoV-2 mutations/variants detected during the study

Time frame: Through the completion of subject participation (up to 15 months after study start date).